Thomas Mika

Thomas Mika Email and Phone Number

EVP & CFO at POET Technologies @ POET Technologies, Inc.
Thomas Mika's Location
San Jose, California, United States, United States
Thomas Mika's Contact Details
About Thomas Mika

In November, 2016 I was appointed EVP & CFO at POET Technologies, a photonics design & development company. POET is positioned to grow rapidly in 2021 with the introduction of the POET Optical Interposer, a disruptive technology and platform for the hybrid integration of photonic and electronic components. Prior to POET, I led the complete restructuring and transformation of a NASDAQ-traded public company from semiconductor capital equipment manufacturer (Tegal Corp.) to medical data analytics (CollabRx), which was later merged with Rennova Health. I have deep experience in corporate restructurings, public and private financings, mergers & acquisitions, and complex, multi-year intellectual property litigation.

Thomas Mika's Current Company Details
POET Technologies, Inc.

Poet Technologies, Inc.

View
EVP & CFO at POET Technologies
Thomas Mika Work Experience Details
  • Poet Technologies, Inc.
    Executive Vice President And Chief Financial Officer
    Poet Technologies, Inc. Nov 2016 - Present
    Toronto, Ontario, Ca
    POET’s Optical Interposer facilitates the co-packaging of electronics and optics in a single Multi-Chip Module (MCM), paving the way for “Photonics-in-a-package”. Based on our dielectric waveguide technology, the Optical Interposer provides the ability to run electrical and optical interconnections side-by-side on the same interposer chip at a micrometer scale. Hybrid Integrated Photonics Packaging (HiPP) enabled by the Optical Interposer plays a critical role in improving electrical and thermal performance, power consumption and form factor of photonics sub-assemblies. The Optical Interposer currently forms an integral part of POET’s hybrid integrated optical engines and leverages the manufacturing processes and unique capabilities of its dielectric waveguides. More information may be obtained at www.poet-technologies.com.
    View
  • Nanovibronix
    Member Of The Board Of Directors, Chairman Of The Audit Committee
    Nanovibronix Jun 2015 - Present
    NanoVibronix is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield and UroShield products are backed by novel technology which relates to ultrasound delivery through surface acoustic waves.
    View
  • Rennova Health, Inc. (Rnva)
    Executive Chairman
    Rennova Health, Inc. (Rnva) Oct 2015 - Nov 2016
    West Palm Beach, Fl, Us
    Rennova Health, Inc. (NASDAQ: RNVA) is a vertically integrated Public Company that provides industry leading Diagnostics and supportive software solutions to healthcare providers. Rennova recognizes that modern healthcare requires a combination of technology and diagnostics to deliver an efficient and effective patient experience and superior clinical outcome. Rennova will continue bringing innovation to healthcare providers and deliver a single source solution through an ever-expanding group of strategic brands that work in unison to empower customers and drive growth. CollabRx, Inc. is a wholly-owned subsidiary of Rennova Health, Inc.
    View
  • Collabrx, Inc.
    President & Ceo
    Collabrx, Inc. Jul 2012 - Nov 2016
    CollabRx, Inc. (NASDAQ: CLRX) CollabRx, Inc. developed and marketed medical information and clinical decision support products and services intended to set a standard for the clinical interpretation of genomics-based, precision medicine. The company was focused on the area of the most critical need - advanced cancer patients who have progressed beyond the standard of care.Building on a comprehensive and specialized knowledge base, software systems that facilitate dynamic updating and automated reporting, and a large network of expert clinical advisors, we developed a suite of unique and differentiated information products and services. These products include a scalable system for providing high-value information on biomarkers and related therapies for inclusion in reports prepared by diagnostic labs reporting on the results from their multi-biomarker genomic-based tests.The Company was merged with Rennova Health, Inc. on November 2, 2016.
  • Sequel Power, Llc
    Executive Chairman
    Sequel Power, Llc Jan 2011 - Mar 2013
    Sequel Power promoted, developed and managed major solar energy projects in the U.S. and abroad, particularly in South America and Saudi Arabia.
  • Tegal Corporation
    President & Ceo
    Tegal Corporation Mar 2005 - Jul 2012
    Petaluma, Ca, Us
    Tegal Corporation was a pioneer in the semiconductor capital equipment industry. Founded in 1972 and acquired by Motorola in 1978, the company was spun-out as an independent company in 1990, and went public on the NASDAQ in 1995. Throughout the 1990's and 2000's the industry became increasingly concentrated, with semiconductor companies relying on capital equipment suppliers for most of their product and process development. Although recognized as an innovative company with enabling technology, Tegal was competitively disadvantaged in a market that placed a high value on size and scale. Several acquisitions in the early 2000's were made to increase Tegal's scale and diversify its product-lines. Taking over as CEO in 2005, I terminated several of these acquisitions, restructured operations and acquired a division of Alcatel-Lucent, eventually almost tripling the company's revenue and turning it profitable in 2007. Ultimately, however, these efforts succumbed to the financial crisis in 2008/09. The Board made the decision to divest the company of its product and intellectual property assets and to pursue emerging technologies in other fields. In 2012, Tegal acquired CollabRx, Inc., a private company, changed its name to CollabRx, Inc. in September 2012, and adopted the mission and goals of CollabRx in the health care / bioinformatics industries.
    View
  • Tegal Corporation
    Executive Vice President & Cfo
    Tegal Corporation Jul 2002 - Mar 2005
    Petaluma, Ca, Us
    As EVP and Chief Financial Officer: - Completed 3 company acquisitions, including Sputtered Films, Inc., First Derivative Systems, Inc. and Simplus Systems, Inc.; - Raised $60M+ in private/public financings; - Successfully pursued complex trade secret litigation against Agilent Technologies, Inc. (later Avago Technologies, Ltd.) over 3 years; and - Managed all aspects of corporate finance and reporting as a NASDAQ-listed public company.
    View
  • International Management Technology Corp. (Imtec)
    Founding Partner
    International Management Technology Corp. (Imtec) 1982 - 2002
    IMTEC was a boutique investment firm that operated from 1982 until the early 2000's. We concluded multiple private equity financings, joint ventures, acquisitions and license agreements on behalf of clients in the health care, pharmaceuticals, media and information technology industries. In addition, when required, we took top management positions in companies in which we founded or invested, including DISC International, Inc. (a software company) and Soupmasters International, Inc. (a chain of quick-service mall-based restaurants).
  • Cresap, Mccormick & Paget, Inc.
    Managing Consultant
    Cresap, Mccormick & Paget, Inc. 1978 - 1982
    Major assignments included Ciba-Geigy Pharmaceuticals Division, US and Global; Ciba-Geigy Konzern Leitung, Basel, Switzerland; UNY Co., Ltd., Nagoya, Japan; Diamond International, Inc., diversified operations, New York, NY
  • Baxter Healthcare
    Summer Intern - Manufacturing Operations
    Baxter Healthcare Jun 1977 - Sep 1977
    Deerfield, Illinois, Us
    View
  • National Science Foundation
    Science Policy Analyst
    National Science Foundation 1973 - 1976
    Alexandria, Va, Us
    Member of the initial 3-person Science Indicators Unit of the National Science Board. Helped to conceive and write "Science Indicators", the bi-annual report of the National Science Board to the President. Developed new benchmark indicators of the state of industrial R&D in the USA versus other countries.
    View
  • Baltimore & Ohio Chicago Terminal Railroad
    Fireman And Roundhouse Hostler
    Baltimore & Ohio Chicago Terminal Railroad 1969 - 1973

Thomas Mika Education Details

  • Harvard Business School
    Harvard Business School
    Mba
  • University Of Illinois Urbana-Champaign
    University Of Illinois Urbana-Champaign
    Applied Violin

Frequently Asked Questions about Thomas Mika

What company does Thomas Mika work for?

Thomas Mika works for Poet Technologies, Inc.

What is Thomas Mika's role at the current company?

Thomas Mika's current role is EVP & CFO at POET Technologies.

What is Thomas Mika's email address?

Thomas Mika's email address is tm****@****hbs.edu

What is Thomas Mika's direct phone number?

Thomas Mika's direct phone number is +170776*****

What schools did Thomas Mika attend?

Thomas Mika attended Harvard Business School, University Of Illinois Urbana-Champaign.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.